Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$FBCD FBC Holding, Inc. (FBCD) Launches Premium High-End Apparel on eBay(TM) Platform.
$FBCD FBC Holding, Inc. (FBCD) Makes Progress to Triple its Apparel Production for Multinational Companies.
$FBCD FBC Holding, Inc. (FBCD) Makes Progress to Triple its Apparel Production for Multinational Companies.
$FBCD FBC Holding, Inc. (FBCD) Set to Exhibit at California Market Fashion Week in Los Ángeles.
$FBCD FBC Holding, Inc. (FBCD) Set to Exhibit at California Market Fashion Week in Los Ángeles.
$NNRX Float 5,733,547,268 07/16/2021. $ERBB Outstanding Shares 3,891,279,720
05/31/2022.
$NNRX Float 5,733,547,268 07/16/2021. $ERBB Outstanding Shares 3,891,279,720
05/31/2022.
$NNRX NutraNomics Files 8K Affirming Acquisition of Fully Licensed Vertically Integrated Cannabis Operation. $CBDD CBD of Denver Signs Licensing Agreement with UK Luxury CBD Brand OTO.
$NNRX NutraNomics Files 8K Affirming Acquisition of Fully Licensed Vertically Integrated Cannabis Operation. $CBDD CBD of Denver Signs Licensing Agreement with UK Luxury CBD Brand OTO.
$NNRX recent acquisition positions the Company for significant upside potential as an emerging leader in the vertically integrated cannabis products space. $CBDD CBD of Denver Expands into Europe's Largest Cannabis Market.
$NNRX recent acquisition positions the Company for significant upside potential as an emerging leader in the vertically integrated cannabis products space. $CBDD CBD of Denver Expands into Europe's Largest Cannabis Market.
$NNRX acquisition of The Plant includes the lease of a 30,000 square foot manufacturing and 28,000 square foot cultivation facility. $ERBB American Green, Inc. Purchases 40,000 square foot Cannabis Grow Building for $3,750,000.
$NNRX acquisition of The Plant includes the lease of a 30,000 square foot manufacturing and 28,000 square foot cultivation facility. $ERBB American Green, Inc. Purchases 40,000 square foot Cannabis Grow Building for $3,750,000.
$NNRX NutraNomics has also already acquired over $2 million in related specialized equipment and continues to invest in productive hard assets for expanded operations involving extraction, production, and materials.
$NNRX NutraNomics has also already acquired over $2 million in related specialized equipment and continues to invest in productive hard assets for expanded operations involving extraction, production, and materials.
$NNRX In 2021, The Plant generated $1.7 million in revenue operating from temporary facilities while the new building was under construction. $ERBB American Green, Inc. New Cannabis Extraction Operation Launched at the Sweet Virginia Grow.
$NNRX In 2021, The Plant generated $1.7 million in revenue operating from temporary facilities while the new building was under construction. $ERBB American Green, Inc. New Cannabis Extraction Operation Launched at the Sweet Virginia Grow.
$NNRX During the Q1 of 2022, manufacturing was transitioned into the new facility, and the Q1 revenue run rate expanded to $879k (appx $3.5M on an annualized basis). $ERBB American Green, Inc.â„¢? Officially Acquires Vendweb - Supplier of Its AGX Facial Recognition and Over- 21 Age Smart Vending Machine
$NNRX During the Q1 of 2022, manufacturing was transitioned into the new facility, and the Q1 revenue run rate expanded to $879k (appx $3.5M on an annualized basis). $ERBB American Green, Inc.â„¢? Officially Acquires Vendweb - Supplier of Its AGX Facial Recognition and Over- 21 Age Smart Vending Machine
$NNRX The overall forecast for 2022 is $15M in total top line sales, making the company cash flow positive through expanded product lines, including beverage powders, tablets, infused pre-rolls and concentrates.
$NNRX The overall forecast for 2022 is $15M in total top line sales, making the company cash flow positive through expanded product lines, including beverage powders, tablets, infused pre-rolls and concentrates.
$NNRX As a holder of California licensing for cannabis cultivation, manufacturing, and distribution, including an active Type 7 manufacturing license for volatile, non-volatile and solventless extraction methods, The Plant possesses broad production capabilities for innovative formulation and delivery methods.
$NNRX As a holder of California licensing for cannabis cultivation, manufacturing, and distribution, including an active Type 7 manufacturing license for volatile, non-volatile and solventless extraction methods, The Plant possesses broad production capabilities for innovative formulation and delivery methods.
$NNRX NutraNomics has a methodical, good-sense approach to identifying and qualifying prospective strategic partners and subsidiary acquisitions.
$NNRX NutraNomics has a methodical, good-sense approach to identifying and qualifying prospective strategic partners and subsidiary acquisitions.
$ATRX Adhera Therapeutics has recently licensed two drug candidates, MLR-1019 and MLR-1023, from the Melior Discovery family of companies. $GILD KU Leuven, Gilead Sciences enter licence agreement to develop antivirals.
$ATRX Adhera Therapeutics has recently licensed two drug candidates, MLR-1019 and MLR-1023, from the Melior Discovery family of companies. $GILD KU Leuven, Gilead Sciences enter licence agreement to develop antivirals.
$ATRX Adhera is developing MLR-1023 (tolimidone) as a new drug for Type I diabetes with a focus on C-peptide positive patients. $PFE Pfizer 3-dose COVID vaccine 80% effective against symptomatic omicron infection for youngest children.
$ATRX Adhera is developing MLR-1023 (tolimidone) as a new drug for Type I diabetes with a focus on C-peptide positive patients. $PFE Pfizer 3-dose COVID vaccine 80% effective against symptomatic omicron infection for youngest children.
$ATRX MLR-1023, a lyn kinase activator, has demonstrated exceptional clinical safety and tolerability in over 700 patients in Phase 2a and Phase 2b Type 2 diabetes studies.
$ATRX MLR-1023, a lyn kinase activator, has demonstrated exceptional clinical safety and tolerability in over 700 patients in Phase 2a and Phase 2b Type 2 diabetes studies.
$ATRX MLR-1019 (armesocarb) is a new class of drug for Parkinson's Disease (PD) and represents the only drug to address both movement and non-movement symptoms of PD. $MRNA Switzerland to destroy more than 620,000 expired Moderna COVID-19 doses
$ATRX MLR-1019 (armesocarb) is a new class of drug for Parkinson's Disease (PD) and represents the only drug to address both movement and non-movement symptoms of PD. $MRNA Switzerland to destroy more than 620,000 expired Moderna COVID-19 doses
$NNRX NutraNomics, Inc. Finalizes Acquisition of DHS Development, Inc. dba The Plant and its Affiliates https://www.otcmarkets.com/stock/NNRX/news/NutraNomics-Inc-Finalizes-Acquisition-of-DHS-Development-Inc-dba-The-Plant-and-its-Affiliates?id=354435
$NNRX NutraNomics, Inc. Finalizes Acquisition of DHS Development, Inc. dba The Plant and its Affiliates https://www.otcmarkets.com/stock/NNRX/news/NutraNomics-Inc-Finalizes-Acquisition-of-DHS-Development-Inc-dba-The-Plant-and-its-Affiliates?id=354435
$NNRX 0.0002 Float
5,733,547,268 07/16/2021
$NNRX 0.0002 Float
5,733,547,268 07/16/2021
$ATRX 0.055 Outstanding Shares 17,493,237 05/02/2022
$ATRX 0.055 Outstanding Shares 17,493,237 05/02/2022
$FBCD 0.0005 Outstanding Shares 2,549,627,869
05/24/2022